Subcutaneous · GLP-1 agonist
PF-04603629
2 trials in this molecule. Source: ClinicalTrials.gov, as of July 6, 2026.
Trials
2
Ongoing
0
Recruiting
0
Completed
1
Sites
5
Countries
1
Endpoints
8
Composite endpoints
0
Distinct sites and countries across this molecule's trials. A site running several of its trials counts once, matching the map.
Where the program stands
Trials by phase
Phase 1
2
Trials by status
Completed
1
Terminated
1
Evidence coverage
What this asset has been measured on
Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.
Safety / tolerability / PK
4
Glycemic / diabetes
2
Other (unclassified)
2
Top 20 metrics across this asset's endpoints
Programs for this asset
Every trial for this molecule, with the same search, filters, and sort as the Trials tab.
⌘K
2 of 2
| Asset / Population | Eligibility highlight | Evidence | ||||||
|---|---|---|---|---|---|---|---|---|
| NCT00637338Multiple Dose Escalation Trial Of PF-04603629 Given To Subjects With Type 2 Diabetes Mellitus | PF-04603629 Type 2 diabetes | BMI 22-40 | Ph 1 | Terminated | 4 | Sep 2008 | - | |
| NCT00638313Single-Dose Study Of PF-04603629 In Type 2 Diabetic Subjects | PF-04603629 Type 2 diabetes | - | Ph 1 | Completed | 2 | Feb 2008 | - |
Showing 1-2 of 2 trials